Streetbeat News

Stock Prices

ZM

Zoom forecasts its adjusted EPS for FY24 to be between $4.93 and $4.95, surpassing the estimated $4.27. The company also projects total revenue to be between $4.506 billion and $4.511 billion, slightly above the $4.5 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:08 pm

ZM

Zoom Video Communications (ZM) exceeded Q3 earnings and sales estimates, with EPS at $1.29 vs. the $1.08 estimate and sales at $1.14B vs. the $1.12B estimate. This reflects a 20.56% increase in EPS and a 3.15% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:06 pm

CENT

Central Garden & Pet (NASDAQ:CENT) reported Q4 earnings with an EPS of $0.1, surpassing the estimate of $0.07 by 42.86%. Revenue increased by $42.70 million compared to the same period last year. The company had previously beaten EPS estimates last quarter, which resulted in a 15.22% share price increase the following day. Historical earnings performance shows mixed results over the past four quarters.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:05 pm

ENTA

Enanta Pharmaceuticals reported a Q4 EPS loss of $(1.33), a 4.72% increase in loss compared to $(1.27) last year. However, their sales of $18.93M exceeded the $17.50M estimate, despite being a 6.83% decrease from the previous year's $20.32M.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:03 pm

RAYA

Erayak Power Solution Group Inc. (NASDAQ: RAYA) received a notification from Nasdaq on November 15, 2023, for not meeting the minimum bid price requirement of $1.00 per share. The company has 180 days until May 13, 2024, to regain compliance. If Erayak's shares close at $1 or higher for 10 consecutive business days, Nasdaq will confirm compliance. Failing to comply within the initial period, Erayak may get an additional 180 days if it meets other listing standards and may consider a reverse stock split to address the issue.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:02 pm

SYM

Symbotic (NASDAQ:SYM) reported Q4 earnings with a loss of $(0.08) per share, surpassing the consensus estimate of $(0.12) by 33.33%. Year-over-year, this reflects a 20% improvement in earnings. The company's quarterly sales reached $392.00M, exceeding expectations by 27.73% and marking a 60.38% increase from the previous year's $244.41M.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 9:01 pm

WST

Over the past 5 years, West Pharmaceutical Servs (NYSE:WST) has produced an average annual return of 26.97%, outperforming the market by 15.41% on an annualized basis. A $1000 investment in WST 5 years ago would be worth $3,299.69 today. West Pharmaceutical Servs currently has a market cap of $25.36 billion.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:00 pm

AJG

Over the past 10 years, Arthur J. Gallagher (NYSE:AJG) has produced an average annual return of 18.07%, outperforming the market. A $1000 investment in AJG a decade ago would now be worth $5,215.79. The company's current market capitalization stands at $53.34 billion.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 9:00 pm

AI

C3.ai's stock is trading lower after reports emerged that the company conducted job cuts last week.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 8:49 pm

GSK

GSK (NYSE:GSK) has seen a 16.67% decrease in short interest, with 4 million shares sold short, representing 0.2% of available shares. The average time to cover these short positions is 1.11 days. Short interest is a market sentiment indicator, and GSK's short interest is below its peer group average of 3.25%. This decline in short interest does not necessarily predict a near-term price rise, but indicates fewer shares are shorted.

Portfolio Pulse from Benzinga Insights

November 20, 2023 | 8:45 pm